Advertisement

A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])

Published:April 25, 2017DOI:https://doi.org/10.1016/j.clgc.2017.04.023

      Abstract

      Background

      Aflibercept is a recombinantly produced fusion protein that has potent anti-vascular endothelial growth factor (VEGF) activity. We tested whether aflibercept has clinical activity in clear-cell renal cell carcinoma (ccRCC). The recommended phase II dose was 4 mg/kg but several patients (pts) treated at 1 mg/kg showed prolonged progression-free survival. We therefore tested both doses in a parallel group randomized trial.

      Patients and Methods

      Eligible pts had histologically confirmed advanced or metastatic ccRCC and previous treatments included exposure to a VEGF receptor tyrosine kinase inhibitor. Pts received aflibercept (either 1 mg/kg or 4 mg/kg) on day 1 of a 14-day cycle until disease progression. Pts randomized to 1 mg/kg could crossover to 4 mg/kg at the time of disease progression. The primary end point was proportion alive and progression-free at 8 weeks. A Simon 2-stage design was used for each arm with 33 and 24 eligible pts per arm enrolled in stages 1 and 2.

      Results

      Ninety-four pts were enrolled, 59 and 35 to 4 mg and 1 mg doses, respectively. Seventy-two percent had 1 previous treatment most commonly sunitinib. Sixteen eligible pts crossed over at the time of disease progression to the 4-mg dose. Most common adverse events were hypertension, proteinuria, and fatigue. Only 4 pts reported Grade 4 or higher toxicity. With 36 of 59 pts (61%) progression-free at 8 weeks, the 4-mg/kg dose met protocol-specified efficacy criteria.

      Conclusion

      Aflibercept is active in previously treated ccRCC and might be worthy of further study.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Mille K.D.
        • Jemal A.
        Cancer statistics, 2016.
        CA Cancer J Clin. 2016; 66: 7-30
        • Pili R.
        • Kauffman E.
        • Rodriguez R.
        Cancer of the kidney.
        in: Niederhuber J.E. Armitage J. Doroshow J.H. Kastan M.D. Tepper J.E. Abeloff's Clinical Oncology. 5th ed. Elsevier, 2013: 1416-1444
        • MacDonald D.A.
        • Martin J.
        • Muthusamy K.K.
        • et al.
        Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
        Angiogenesis. 2016; 19: 389-406
        • Holash J.
        • Davis S.
        • Papadopoulos N.
        • et al.
        VEGF-Trap: a VEGF blocker with potent antitumor effects.
        Proc Natl Acad Sci U S A. 2002; 99: 11393-11398
        • Verheul H.H.
        • Hammers H.
        • van Erp K.
        • et al.
        VEGF Trap is a potent inhibitor of tumor growth and spontaneous lung metastases in murine renal cell carcinoma.
        Clin Cancer Res. 2007; 13: 4201-4208
        • Van Cutsem E.
        • Tabernero J.
        • Lakomy R.
        • et al.
        Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
        J Clin Oncol. 2012; 30: 3499-3506
        • Motzer R.J.
        • Murphy B.A.
        • Bacik J.
        • et al.
        Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
        J Clin Oncol. 2000; 18: 2972-2980
        • Kaplan E.L.
        • Meier P.
        Nonparametric estimation of incomplete observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Albiges L.
        • Choueiri T.
        • Escudier B.
        • et al.
        A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
        Eur Urol. 2015; 67: 100-110
        • Choueiri T.K.
        • Escudier B.
        • Powles T.
        • et al.
        Cabozantinib versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 373: 1814-1823
        • Motzer R.J.
        • Hutson T.E.
        • Glen H.
        • et al.
        Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
        Lancet Oncol. 2015; 16: 1473-1482
        • Motzer R.J.
        • Escudier B.
        • McDermott D.F.
        Nivolumab versus everolimus in advanced renal-cell carcinoma.
        N Engl J Med. 2015; 19: 1803-1813
        • Rini B.I.
        • Escudier B.
        • Tomczak P.
        • et al.
        Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
        Lancet. 2011; 378: 1931-1939
        • Escudier B.
        • Pluzanska A.
        • Koralewski P.
        • et al.
        Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
        Lancet. 2007; 370: 2103-2111
        • Rini B.I.
        • Halabi S.
        • Rosenberg J.E.
        • et al.
        Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
        J Clin Oncol. 2008; 26: 5422-5428
        • Bukowski R.M.
        • Kabbinavar F.F.
        • Figlin R.A.
        • et al.
        Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
        J Clin Oncol. 2007; 25: 4536-4541
        • Turnbull J.D.
        • Cobert J.
        • Jaffe T.
        • et al.
        Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
        Clin Genitourin Cancer. 2013; 11: 45-50
        • Yang J.C.
        • Haworth L.
        • Sherry R.M.
        • et al.
        A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
        N Engl J Med. 2003; 349: 427-434
        • Chen W.
        • Hill H.
        • Christie A.
        • et al.
        Targeting renal cell carcinoma with an HIF-2 antagonist.
        Nature. 2016; 539: 112-117
        • Cho H.
        • Du X.
        • Rizzi J.P.
        • et al.
        On-target efficacy of an HIF2α antagonist in preclinical kidney cancer models.
        Nature. 2016; 539: 107-111